Company Filing History:
3 out of 291 
2 out of 1,289 
Years Active: 2011-2022
Title: Philippe Patrick Monnier: Innovator in Neuroscience
Introduction
Philippe Patrick Monnier is a notable inventor based in Toronto, Canada. He has made significant contributions to the field of neuroscience, particularly in the development of agents that modulate critical interactions in neuronal health. With a total of 5 patents, his work has the potential to impact treatments for various neurological conditions.
Latest Patents
Monnier's latest patents include innovative methods and agents directed against a cis RGMa/neogenin interaction or lipid rafts. These agents are designed to block the interaction between Repulsive Guidance Molecule A (RGMa) and Neogenin, promoting neuronal cell survival and axon growth. Additionally, he has developed methods for treating diseases by administering these agents to subjects in need. Another significant patent focuses on methods and compositions for modulating blood-brain barrier integrity and promoting re-myelination. These compositions include RGMa, soluble RGMa, and Neogenin peptides, which are crucial for enhancing the delivery of therapeutic agents to the brain.
Career Highlights
Throughout his career, Monnier has worked with esteemed institutions such as the University Health Network and the Max Planck Society for the Advancement of Science. His research has been pivotal in advancing our understanding of neuronal interactions and their implications for treatment.
Collaborations
Monnier has collaborated with notable colleagues, including Nardos G Tassew and Bernhard K Mueller. Their joint efforts have contributed to the development of innovative solutions in the field of neuroscience.
Conclusion
Philippe Patrick Monnier's work exemplifies the intersection of innovation and neuroscience, with his patents paving the way for new treatments in neurological health. His contributions are invaluable to the scientific community and hold promise for future advancements in the field.